Hairy cell leukemia(HCL) is a rare malignant hematological tumor. This article presents the diagnosis and treatment of a patient with recurrent HCL. This patient, a 51-year-old female, was diagnosed with HCL in June 2013 and subsequently received monotherapy with cladribine. Post-treatment evaluation indicated a partial remission. In November 2023, she experienced chest tightness and shortness of breath with ultrasound revealing a right-sided pleural effusion. A follow-up examination in February 2024 confirmed the relapse of HCL. She was then treated with a combination of vemurafenib and rituximab, which resulted in a rapid complete remission without minimal residual disease. This case provides valuable insights into the management of recurrent HCL.

Objective To identify genes regulated by ME2 and to explore their roles as well as underlying mecha-nisms in liver cancer progression.Methods RNA-seq data of siME2-transfected cells were subjected to differential expression analysis,clustering,GO and KEGG enrichment analyses.The mRNA level of the potential target gene SHCBP1 was measured by quantitative real-time PCR(qPCR)following ME2 knockdown or overexpression in HepG2 cells.The effect of ME2 and SHCBP1 on the downstream pathway was examined by Western blot.Cell pro-liferation,wound healing,and colony formation assays were conducted to evaluate SHCBP1's role in liver cancer cell proliferation and migration.Survival analysis of the TCGA-LIHC cohort was performed to determine the prog-nostic value of SHCBP1 in liver cancer patients.Results Differentially expressed genes in siME2-transfected cells were significantly enriched in biological processes including the PI3K-Akt signaling pathway,cell cycle,and serine phosphorylation.In HepG2 cells,ME2 knockdown led to a reduction in SHCBP1 mRNA level,whereas ME2 over-expression resulted in enhanced SHCBP1 mRNA level,demonstrating a positive correlation between ME2 and SHCBP1 expression.Western blot analysis revealed that ME2 enhanced PI3K-Akt signaling pathway activation through SHCBP1.qPCR results confirmed that SHCBP1 was significantly over-expressed in liver cancer cells and promoted both proliferation and migration,contributing to poor prognosis in liver cancer patients.Conclusions ME2 promotes liver cancer progression by regulating SHCBP1 to activate the PI3K-Akt signaling pathway,presen-ting a novel therapeutic target for liver cancer treatment.

Objective:To compare the aortic remodeling of the Fabulous stent system and standard thoracic aortic endovascular repair (TEVAR) on distal aorta type B aortic dissection (TBAD). Methods:The prospective data collected between Dec 2017 and Oct 2019 from 134 patients with type B aortic dissection (TBAD) who underwent treatment with the "Fabulous" stent system, and retrospective data from 159 TBAD patients receiving standard TEVAR from corresponding multicenter. By using propensity score matching analysis, we compared the prognosis and aortic remodeling outcomes in patients undergoing Fabulous and standard TEVAR treatments during a 1-year postoperative follow-up.Results:In this study, 62 patients in Fabulous group and 62 patients in standard TEVAR were included.There were no significant statistical differences in baseline characteristics between the two groups. In terms of aortic remodeling in bare stent region, Fabulous group had better change trends of diameter of true lumen [10.6 (4.4, 14.5) mm vs. 4.7 (0.9, 10.7) mm, P=0.001] and false lumen [-24.2 (-30.5, -4.9) mm vs. 0.7 (-11.8, 2.3) mm, P<0.001] than those in the standard TEVAR group. The rate of complete false lumen thrombosis was also higher in the Fabulous group (62.9% vs. 37.1%, P=0.042). Conclusion:The Fabulous stent system, when compared to standard TEVAR surgery, demonstrates good aortic remodeling outcomes in the distal aorta.